Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

Exclusion Criteria

• •Subject has greater than two (2) facial nodules;
• •Subject has any skin pathology or condition that could interfere with the investigator's clinical evaluation of the investigational drug;
• •Subject has used topical and systemic anti-acne medications or therapies;
• •Subject has received hormonal therapy for acne treatment;
• •Subject has used a skincare product with acne removal effect;
• •Subject has other serious underlying diseases such as mental illness or malignant tumors;
• •Subject has any of the clinically significant laboratory test indicators at screening;
• •Subject has known hypersensitivity or previous allergic reaction to multiple drugs, or any of the active or inactive components of the test articles;
• •Subject engaged in drug abuse or excessive alcohol intake;
• •Subject has uncontrolled hypertension; Subject has poorly controlled diabetes;
• •Subject is pregnant, lactating, or is planning to become pregnant during the study (both male and female); subject has positive pregnancy test result; subject is unable to practice highly effective contraception methods during the trial and within 3 months after the end of the trial;
• •Subject is currently enrolled or was enrolled in other clinical trials within 3 months prior to the initiation of treatment;
• •Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this clinical trial.